ArticlePloS one2026
The role of SALL1-MGST1 axis-mediated ferroptosis inhibition in chemoresistance of retinoblastoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoblastoma (RB) is the most prevalent intraocular malignant tumor in infants and young children, predominantly driven by the biallelic inactivation of the RB1 gene. Although multimodal treatment strategies have markedly improved the survival rates of pediatric patients, chemotherapy resistance, particularly carboplatin (CBP) resistance, remains a major clinical hurdle. In recent years, ferroptosis, an iron-dependent and lipid peroxide-driven form of programmed cell death, has garnered significant attention for its role in tumor drug resistance. This study investigates the functional mechanisms of the transcription factor Spalt-Like Transcription Factor 1 (SALL1) and its downstream target gene Microsomal Glutathione S-Transferase 1 (MGST1) in RB. Bioinformatics analysis revealed a significant upregulation of SALL1 in RB, accompanied by enhanced activity of its regulatory network. Experimental evidence from ChIP-qPCR and luciferase reporter assays indicated that SALL1 binds to the promoter region of MGST1 and enhances its promoter transcriptional output. Functionally, knockdown of SALL1 suppressed cell proliferation and induced ferroptosis, as evidenced by increased levels of lipid peroxidation, elevated malondialdehyde (MDA), and decreased glutathione (GSH) levels. These effects were reversible by the ferroptosis inhibitor Fer-1 or overexpression of MGST1. In the CBP-resistant cell line Y79-R, knockdown of SALL1 notably reduced the IC50, enhanced chemosensitivity, and promoted cell death, a phenotype that could be rescued by overexpression of MGST1. Mechanistically, the SALL1-MGST1 axis promotes RB cell survival and drug resistance by inhibiting lipid peroxidation and ferroptosis. This study is the first to elucidate that the SALL1-MGST1 axis mediates CBP resistance in RB through the regulation of ferroptosis, providing a novel therapeutic target for reversing drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.